GlassScriptPhysician profile
Narbeh Tovmassian
NPI 1750643508
$3,503.61
in general payments reported to CMS, 2019-2025
17 companies · $315 in 2025
The $315 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,305 · 2020: $146 · 2021: $577 · 2022: $463 · 2023: $426 · 2024: $271 · 2025: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,012.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,075.89 | 2019-2024 | Xarelto |
| Abbott Laboratories | $716.58 | 2019-2025 | Mitraclip |
| Boston Scientific Corporation | $644.02 | 2019-2023 | Resonate El Icd Vr |
| Abiomed | $285.58 | 2023-2024 | Impella |
| Organogenesis INC. | $173.75 | 2025 | Cygnus Dual |
| Medtronic, INC. | $132.36 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $113.23 | 2021 | |
| Lilly USA, LLC | $108.09 | 2023 | Mounjaro, Trulicity |
| Phathom Pharmaceuticals, INC. | $47.84 | 2025 | Voquezna |
| Astellas Pharma US INC | $45.94 | 2021 | |
| Gilead Sciences, INC. | $33.85 | 2024 | |
| Pfizer INC. | $27.40 | 2023 | |
| Novo Nordisk INC | $23.25 | 2025 | Wegovy |
| Ironwood Pharmaceuticals, INC | $22.30 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $19.78 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $18.49 | 2019 | |
| Dexcom, INC. | $15.26 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narbeh Tovmassian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.